Effectiveness of emicizumab in preventing bleeding events in severe and moderate hemophilia A: A single‐center experience in Bangladesh

Effectiveness of emicizumab in preventing bleeding events in severe and moderate hemophilia A: A single‐center experience in Bangladesh

Abstract Emicizumab is a monoclonal antibody that bridges activated factor IX (FIX) and factor X (FX) to replace the function of missing activated factor VIII (FVIII) in hemophilia A patients irrespective of FVIII inhibitor status. This study assessed the effectiveness of emicizumab in preventing bl...

Full description

Bibliographic Details
Main Authors: Sanzina Sadia Tory, Sujan Ghosh, Humayra Nazneen, Nurul Farhad, Salwa Islam, Mohammad Jahid Hasan, Akhil Ranjan Biswas
Format: Article
Language:English
Published: Wiley 2024-02-01
Series:eJHaem
Subjects:
annualized bleeding rate
efficacy
emicizumab
hemophilia A
prophylaxis
safety
Online Access:https://doi.org/10.1002/jha2.832

Internet

https://doi.org/10.1002/jha2.832

Similar Items